ASPG and acute lymphoblastic leukemia: Since both DCOG ALL10 and AIEOP-BFM ALL 2000 have intensive induction and post-remission therapy, the difference in EFS in the MR arms might, besides differences in use of asparaginase and pulses, be due to a larger part of DCOG ALL10 patients being stratified in MR, 60.1% vs. 44.5% respectively, thereby including more “lower risk” patients in the MR arm.